EA201591478A1 - Биспецифические антитела против фно и ил-17 - Google Patents

Биспецифические антитела против фно и ил-17

Info

Publication number
EA201591478A1
EA201591478A1 EA201591478A EA201591478A EA201591478A1 EA 201591478 A1 EA201591478 A1 EA 201591478A1 EA 201591478 A EA201591478 A EA 201591478A EA 201591478 A EA201591478 A EA 201591478A EA 201591478 A1 EA201591478 A1 EA 201591478A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bispecific antibodies
antibodies against
against tnf
tnf
psa
Prior art date
Application number
EA201591478A
Other languages
English (en)
Inventor
Барретт Аллан
Эндрю Лоренс Глейсбрук
Донмиенн Доен Мун Леунг
Цзижун Лу
Ин Тан
Эндрю Чарльз Вендел
Деррик Райан Уитчер
Пиа Паулина Ячи
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201591478A1 publication Critical patent/EA201591478A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описаны биспецифические антитела, специфически связывающие и фактор некроза опухоли альфа (ФНО-α), и интерлейкин-17 (IL-17). Биспецифические антитела согласно изобретению могут найти применение в лечении различных аутоиммунных заболеваний, в том числе ревматоидного артрита (РА), псориатического артрита (ПсА) и анкилозирующего спондилита (АС).
EA201591478A 2013-03-08 2014-03-04 Биспецифические антитела против фно и ил-17 EA201591478A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774909P 2013-03-08 2013-03-08
PCT/US2014/020062 WO2014137961A1 (en) 2013-03-08 2014-03-04 Anti-tnf-anti-il-17 bispecific antibodies

Publications (1)

Publication Number Publication Date
EA201591478A1 true EA201591478A1 (ru) 2016-03-31

Family

ID=50343854

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591478A EA201591478A1 (ru) 2013-03-08 2014-03-04 Биспецифические антитела против фно и ил-17

Country Status (16)

Country Link
US (1) US9416182B2 (ru)
EP (1) EP2964674B1 (ru)
JP (1) JP6152433B2 (ru)
KR (1) KR20150113199A (ru)
CN (1) CN105283467B (ru)
AP (1) AP2015008709A0 (ru)
AR (1) AR094872A1 (ru)
AU (1) AU2014226093A1 (ru)
BR (1) BR112015018203A2 (ru)
CA (1) CA2896888C (ru)
EA (1) EA201591478A1 (ru)
ES (1) ES2654681T3 (ru)
MX (1) MX2015011957A (ru)
TW (1) TW201444867A (ru)
WO (1) WO2014137961A1 (ru)
ZA (1) ZA201506568B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10220076B2 (en) 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
TW201639596A (zh) * 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
CN106661117B (zh) * 2015-12-30 2020-11-17 深圳先进技术研究院 IgG杂合型抗TNFα和IL-17A双特异性抗体
EP3408293A4 (en) * 2016-01-28 2019-09-11 Janssen Biotech, Inc. BISPECIFIC ANTI-TNF-ALPHA / IL-17A ANTIBODY ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS OF USE
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
WO2018008750A1 (ja) * 2016-07-08 2018-01-11 ＴＡＫ－Ｃｉｒｃｕｌａｔｏｒ株式会社 インターロイキン６、インターロイキン１３、ｔｎｆ、ｇ－ｃｓｆ、ｃｘｃｌ１、ｃｘｃｌ２、又はｃｘｃｌ５に起因する疾病の予防又は治療剤をスクリーニングする方法、及びインターロイキン６、インターロイキン１３、ｔｎｆ、ｇ－ｃｓｆ、ｃｘｃｌ１、ｃｘｃｌ２、又はｃｘｃｌ５に起因する疾病の予防又は治療剤
CN107857818A (zh) * 2017-08-07 2018-03-30 上海科新生物技术股份有限公司 一种针对IL‑17和TNF‑α的双特异性融合蛋白
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
TWI825214B (zh) * 2018-11-05 2023-12-11 中國大陸商北京韓美藥品有限公司 抗TNFα/抗IL-17A天然抗體結構樣異源二聚體形式雙特異抗體及其製備
US20220127350A1 (en) 2019-01-31 2022-04-28 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
WO2022072291A1 (en) * 2020-09-30 2022-04-07 Amgen Inc. Cation exchange chromatography process
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007070750A1 (en) 2005-12-13 2007-06-21 Eli Lilly And Company Anti-il-17 antibodies
EP3825329A1 (en) * 2007-12-26 2021-05-26 Xencor, Inc. Fc variants with altered binding to fcrn
AR075798A1 (es) 2009-03-05 2011-04-27 Abbott Lab Proteinas de union a il-17 (interleuquina 17)
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
CA2896888A1 (en) 2014-09-12
MX2015011957A (es) 2016-04-07
JP6152433B2 (ja) 2017-06-28
CN105283467A (zh) 2016-01-27
BR112015018203A2 (pt) 2017-08-22
EP2964674B1 (en) 2017-11-08
TW201444867A (zh) 2014-12-01
AP2015008709A0 (en) 2015-09-30
ZA201506568B (en) 2017-11-29
EP2964674A1 (en) 2016-01-13
US9416182B2 (en) 2016-08-16
CA2896888C (en) 2017-11-21
AR094872A1 (es) 2015-09-02
JP2016510743A (ja) 2016-04-11
CN105283467B (zh) 2019-04-02
WO2014137961A1 (en) 2014-09-12
KR20150113199A (ko) 2015-10-07
AU2014226093A1 (en) 2015-07-23
ES2654681T3 (es) 2018-02-14
US20140255406A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MY191649A (en) Antibodies to tigit
MX2018006072A (es) Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
EA201791485A1 (ru) Анти-cd47-антитела и их применения
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
WO2015109124A3 (en) Immunomodulatory agents
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JOP20140049B1 (ar) أجسام مضادة ترتبط بـ il-23
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201591898A1 (ru) Антитела, направленные на m-csf
EA202090128A3 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения